All Stories

  1. Bone Marker Proteins at Baseline and After Insulin-Induced Hypoglycaemia in Type 2 Diabetes
  2. Bone Marker Proteins in Women With and Without Polycystic Ovary Syndrome
  3. Differential Expression of Complement Pathway Components in Unexplained Infertility Versus Male Factor Infertility: Insights from an Exploratory Pilot Study
  4. Exploring the interaction between ethnicity, deprivation and the use of CGM on diabetes outcomes—A study from the Association of British Clinical Diabetologists
  5. Baseline clinical factors associated with diabetes distress in dialysis patients: Insights from the ABCD audit data
  6. Machine learning identifies waist-height ratio (WHtR) as the strongest determinant of diabetes and prediabetes in children and adolescents: A comprehensive national nutrition survey
  7. Endothelial Protein Changes Indicative of Endometriosis in Unexplained Infertility, an Exploratory Study
  8. Comprehensive Analysis of Psychological, Social and Clinical Aspects of Polycystic Ovary Syndrome in Pregnancy: Insights From the Born in Bradford Cohort Study
  9. Association of Complement Proteins with C Reactive Protein in Non-Obese Women with and Without Polycystic Ovary Syndrome
  10. A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome
  11. Time Below Range and Its Influence on Hypoglycemia Awareness and Severe Hypoglycemia: Insights From the Association of British Clinical Diabetologists Study
  12. Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Their Ratios in Women with Polycystic Ovary Syndrome and Healthy Controls
  13. Cardiovascular Risk Biomarkers in Women with and Without Polycystic Ovary Syndrome
  14. Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non‐insulin therapies—A randomised controlled trial
  15. Molecular Aspects of Cardiovascular Risk Factors
  16. Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR)
  17. A Cross-Sectional Exploratory Study of Cardiovascular Risk Biomarkers in Non-Obese Women with and without Polycystic Ovary Syndrome: Association with Vitamin D
  18. Association of Vitamin D with Perfluorinated Alkyl Acids in Women with and without Non-Obese Polycystic Ovary Syndrome
  19. Effect of Hypoglycemia and Rebound Hyperglycemia on Proteomic Cardiovascular Risk Biomarkers
  20. A Cross-Sectional Study of Glomerular Hyperfiltration in Polycystic Ovary Syndrome
  21. Medicinal Plants for the Treatment of Neuropathic Pain: A Review of Randomized Controlled Trials
  22. A Cross-Sectional Study of Protein Changes Associated with Dementia in Non-Obese Weight Matched Women with and without Polycystic Ovary Syndrome
  23. A Cross-Sectional Study of Alzheimer-Related Proteins in Women with Polycystic Ovary Syndrome
  24. Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation
  25. Molecular Mechanisms Linking Diabetes with Increased Risk of Thrombosis
  26. Correlation between socio-demographic characteristics, metabolic control factors and personality traits with self-perceived health status in patients with diabetes: A cross-sectional study
  27. The Effect of a Very-Low-Calorie Diet (VLCD) vs. a Moderate Energy Deficit Diet in Obese Women with Polycystic Ovary Syndrome (PCOS)—A Randomised Controlled Trial
  28. Complement Dysregulation in Obese Versus Nonobese Polycystic Ovary Syndrome Patients
  29. Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus
  30. Oxidative Stress Markers and Heat Shock Proteins in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D
  31. The pleiotropic effects of statins in rheumatoid arthritis
  32. The Role of High-density Lipoprotein in Oral and Dental Diseases
  33. Association between Organochlorine Pesticides and Vitamin D in Female Subjects
  34. HDL-Associated Proteins in Subjects with Polycystic Ovary Syndrome: A Proteomic Study
  35. Coagulation factor dysregulation in polycystic ovary syndrome is an epiphenomenon of obesity
  36. A review on curcumin colon-targeted oral drug delivery systems for the treatment of inflammatory bowel disease
  37. Modulatory properties of curcumin in cancer: A narrative review on the role of interferons
  38. Curcumin‐piperine co‐supplementation and human health: A comprehensive review of preclinical and clinical studies
  39. Diagnostic Value of Non-invasive Liver Function Tests in Liver Fibrosis and Changes in These Parameters Post-metabolic Surgery
  40. MicroRNA Changes Up to 24 h following Induced Hypoglycemia in Type 2 Diabetes
  41. Assessing the androgenic and metabolic heterogeneity in polycystic ovary syndrome using cluster analysis
  42. Components of the Complement Cascade Differ in Polycystic Ovary Syndrome
  43. Protective effects of curcumin on ischemia/reperfusion injury
  44. Inflammatory Markers in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D Metabolites
  45. The Translational Role of miRNA in Polycystic Ovary Syndrome: From Bench to Bedside—A Systematic Literature Review
  46. Therapeutic effects of statins on osteoarthritis: A review
  47. Phytochemicals as Modulators of Paraoxonase-1 in Health and Diseases
  48. Abnormal Uterine Bleeding in Perimenopausal Women: The Role of Hysteroscopy and Its Impact on Quality of Life and Sexuality
  49. Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response
  50. Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials
  51. Anti-Proliferative Potential of Fluorinated Curcumin Analogues: Experimental and Computational Analysis and Review of the Literature
  52. Diagnostic and Prognostic Protein Biomarkers of β-Cell Function in Type 2 Diabetes and Their Modulation with Glucose Normalization
  53. Astaxanthin and Nrf2 Signaling Pathway: A Novel Target for New Therapeutic Approaches
  54. The cardioprotective effects of nano‐curcumin against doxorubicin‐induced cardiotoxicity: A systematic review
  55. The effects of phytochemicals and herbal bio-active compounds on tumour necrosis factor-α in overweight and obese individuals: a clinical review
  56. Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta‐analysis of randomized controlled trials
  57. A case-control study of polychlorinated biphenyl association with metabolic and hormonal outcomes in polycystic ovary syndrome
  58. Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials
  59. Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
  60. Effect of pharmacological interventions on lipid profiles and C‐reactive protein in polycystic ovary syndrome: A systematic review and meta‐analysis
  61. Heat Shock-Related Protein Responses and Inflammatory Protein Changes Are Associated with Mild Prolonged Hypoglycemia
  62. siRNA Therapeutics: Future Promise for Neurodegenerative Diseases
  63. Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
  64. Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta‐analysis of randomized controlled trials
  65. The effects of herbal medicines on cancer therapy‐induced oral mucositis: A literature review
  66. Effect of curcumin on C‐reactive protein as a biomarker of systemic inflammation: An updated meta‐analysis of randomized controlled trials
  67. Impaired Awareness of Hypoglycemia and Severe Hypoglycemia in Drivers With Diabetes: Insights From the Association of British Clinical Diabetologists Nationwide Audit
  68. Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders
  69. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
  70. Effect of curcumin on proinflammatory cytokines: A meta-analysis of randomized controlled trials
  71. The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
  72. Predictors of diabetes‐related distress before and after FreeStyle Libre‐1 use: Lessons from the A ssociation of B ...
  73. Love is in the hair: arginine methylation of human hair proteins as novel cardiovascular biomarkers
  74. Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity
  75. Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection?
  76. Roux-en-Y gastric bypass-induced bacterial perturbation contributes to altered host-bacterial co-metabolic phenotype
  77. Author response for "Predictors of Diabetes‐related Distress ( DRD ) before and after FreeStyle Libre‐1 use: Lessons from Association of British Clinical Diabetologists ( ABCD ) nationwide study"
  78. Vitamin D association with coagulation factors in polycystic ovary syndrome is dependent upon body mass index
  79. 132-OR: Prolonged Mild Hypoglycemia Elicits Greater Heat Shock Protein Responses than Severe Transient Hypoglycemia
  80. Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664
  81. The Effect of Combined Vitamin C and Vitamin E Supplementation on Oxidative Stress Markers in Women with Endometriosis: A Randomized, Triple-Blind Placebo-Controlled Clinical Trial
  82. The Effect of Free Androgen Index on the Quality of Life of Women With Polycystic Ovary Syndrome: A Cross-Sectional Study
  83. The predictive role of parathyroid hormone for non-alcoholic fatty liver disease based on invasive and non-invasive findings in candidates of bariatric surgery
  84. The Association of the Polychlorinated Biphenyl Class of Endocrine Disruptors With Polycystic Ovary Syndrome and Thyroid Dysfunction
  85. Regulation of circulating CTRP-2/CTRP-9 and GDF-8/GDF-15 by intralipids and insulin in healthy control and polycystic ovary syndrome women following chronic exercise training
  86. Impact of curcumin on fatty acid metabolism
  87. Amyloid-related protein changes associated with dementia differ according to severity of hypoglycemia
  88. Plasma heat shock protein response to euglycemia in type 2 diabetes
  89. Glucose excursions in type 2 diabetes modulate amyloid-related proteins associated with dementia
  90. Platelet Protein-Related Abnormalities in Response to Acute Hypoglycemia in Type 2 Diabetes
  91. Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19
  92. Correction to: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
  93. Effect of COVID-19 on Mortality of Pregnant and Postpartum Women: A Systematic Review and Meta-Analysis
  94. Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
  95. Mapping of type 2 diabetes proteins to COVID-19 biomarkers: A proteomic analysis
  96. The Role of Interleukin-18 in the Development and Progression of Atherosclerosis
  97. The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome
  98. The role of myeloid-derived suppressor cells in rheumatoid arthritis: An update
  99. Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?
  100. Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome
  101. Pulmonary fibrosis: Therapeutic and mechanistic insights into the role of phytochemicals
  102. The Impact of Immune Cell-derived Exosomes on Immune Response Initiation and Immune System Function
  103. Postload glucose spike but not fasting glucose determines prognosis after myocardial infarction in patients without known or newly diagnosed diabetes
  104. Application of Erythropoietin in Chronic Heart Failure Treatment
  105. Antioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
  106. Role of Curcumin in Regulating Long Noncoding RNA Expression in Cancer
  107. The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial
  108. The Effects of Nutraceuticals and Herbal Medicine on Candida albicans in Oral Candidiasis: A Comprehensive Review
  109. [Retracted] Urinary Angiogenin as a Marker for Bladder Cancer: A Meta‐Analysis
  110. A Survey of Psychological Distress Among the Community in the COVID-19 Epidemic: A Cross-Sectional Study
  111. Cardiac Injury in COVID-19: A Systematic Review
  112. Coronavirus (COVID-19)-Associated Psychological Distress Among Medical Students in Iran
  113. Depression, Anxiety, and Stress Among Patients with COVID-19: A Cross-Sectional Study
  114. Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis
  115. Adoptive transfer of Tregs: A novel strategy for cell-based immunotherapy in spontaneous abortion: Lessons from experimental models
  116. Letter to the Editor: Do biomarkers of COVID-19 severity simply reflect a stress response in type 2 diabetes: Biomarker response to hypoglycemia
  117. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence
  118. Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice
  119. Type 2 diabetes is an independent predictor of weight loss in Tier 3 Weight Assessment and Management Services
  120. COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
  121. Counteracting arsenic toxicity: Curcumin to the rescue?
  122. The Impact of Diabetes Mellitus in COVID-19: A Mechanistic Review of Molecular Interactions
  123. Macrophage activation in obese type 2 diabetes: an enhanced risk for COVID-19 and Acute Respiratory Distress Syndrome?
  124. Evaluation of the effect of curcumin on pneumonia: A systematic review of preclinical studies
  125. Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations
  126. Integrin‐associated ILK and PINCH1 protein content are reduced in skeletal muscle of maintenance haemodialysis patients
  127. Does high-normal 2-hour post load plasma glucose after myocardial infarction in patients with normal glucose tolerance adversely affect prognosis?
  128. Post-load glucose spike is a determinant of post-MI prognosis in patients without known or newly diagnosed diabetes
  129. Pro-fibrotic M2 macrophage markers may increase the risk for COVID19 in type 2 diabetes with obesity
  130. Recent advances in drug discovery for diabetic kidney disease
  131. Macrophage activation in obese type 2 diabetes: an enhanced risk for COVID-19 and Acute Respiratory Distress Syndrome?
  132. Hypoglycaemia in type 2 diabetes exacerbates amyloid‐related proteins associated with dementia
  133. Long non-coding RNA expression in non-obese women with polycystic ovary syndrome and weight-matched controls
  134. miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review
  135. Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women
  136. Increased MicroRNA Levels in Women With Polycystic Ovarian Syndrome but Without Insulin Resistance: A Pilot Prospective Study
  137. Hyperthyroidism and bone mineral density: Dissecting the causal association with Mendelian randomization analysis
  138. Antipsychotic Drugs and Risk of Developing Venous Thromboembolism and Pulmonary Embolism: A Systematic Review and Meta-Analysis
  139. Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review
  140. Author response for "Hypoglycemia in Type 2 Diabetes exacerbates Amyloid‐related proteins associated with dementia"
  141. Metabolic Consequences Of Obesity On The Hypercoagulable State Of Polycystic Ovary Syndrome: A Risk For Severe SARS-Cov-2 Infection?
  142. Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction
  143. Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?
  144. Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu
  145. Integrative role of traditional and modern technologies to combat COVID-19
  146. Obesity and Insulin Resistance: A Review of Molecular Interactions
  147. Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses
  148. Corrigendum: microRNA Expression in Women With and Without Polycystic Ovarian Syndrome Matched for Body Mass Index
  149. Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit
  150. Renin-Angiotensin System Overactivation in Type 2 Diabetes: A Risk for SARS-CoV-2 Infection?
  151. Potential effects of curcumin in the treatment of COVID‐19 infection
  152. Author Correction: Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects
  153. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
  154. Association of endocrine active environmental compounds with body mass index and weight loss following bariatric surgery
  155. The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
  156. Curcumin for the management of periodontal diseases: a review
  157. The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review
  158. The effect of aromatherapy with rose and lavender on anxiety, surgical site pain, and extubation time after open‐heart surgery: A double‐center randomized controlled trial
  159. Newly diagnosed abnormal glucose tolerance determines post-MI prognosis in patients with hospital related hyperglycaemia but without known diabetes
  160. Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects
  161. Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus
  162. Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
  163. Incretins and microRNAs: Interactions and physiological relevance
  164. MicroRNA-mediated regulation of Nrf2 signaling pathway: Implications in disease therapy and protection against oxidative stress
  165. Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and application to healthy volunteers: A viable workflow and a cautionary tale
  166. The molecular mechanisms by which vitamin D improve glucose homeostasis: A mechanistic review
  167. Harnessing CRISPR/Cas9 technology in cardiovascular disease
  168. Neuromodulatory effects of anti-diabetes medications: A mechanistic review
  169. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
  170. Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
  171. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review
  172. The Role of MicroRNAs in Regulating Cytokines and Growth Factors in Coronary Artery Disease: The Ins and Outs
  173. Two-Hour Post-Load Plasma Glucose, a Biomarker to Improve the GRACE Score in Patients without Known Diabetes
  174. The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review
  175. Comparative Evaluation of Biomarkers of Inflammation Among Indian Women With Polycystic Ovary Syndrome (PCOS) Consuming Vegetarian vs. Non-vegetarian Diet
  176. Expression of microRNA in follicular fluid in women with and without PCOS
  177. Severe proximal myopathy with high creatine kinase levels secondary to Hashimoto's thyroiditis
  178. Going to extremes: the Goldilocks/Lagom principle and data distribution
  179. The effect of C-peptide on diabetic nephropathy: A review of molecular mechanisms
  180. Cell transfer‐based immunotherapies in cancer: A review
  181. Effects of curcumin on mitochondria in neurodegenerative diseases
  182. Alterations in long noncoding RNAs in women with and without polycystic ovarian syndrome
  183. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
  184. Serum measures of hexabromocyclododecane (HBCDD) and polybrominated diphenyl ethers (PBDEs) in reproductive-aged women in the United Kingdom
  185. Diet and Nutritional Interventions with the Special Role of Myo-Inositol in Gestational Diabetes Mellitus Management. An Evidence-Based Critical Appraisal
  186. Anti-fibrotic effects of curcumin and some of its analogues in the heart
  187. The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects
  188. A review of the pharmacological and therapeutic effects of auraptene
  189. Correction to: Curcumin: a modulator of inflammatory signaling pathways in the immune system
  190. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
  191. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
  192. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
  193. Severe proximal myopathy secondary to Hashimoto’s thyroiditis
  194. Targeting the balance of T helper cell responses by curcumin in inflammatory and autoimmune states
  195. Is Weight Loss Harmful for Skeletal Health in Obese Older Adults?
  196. Medicinal plants in traumatic brain injury: Neuroprotective mechanisms revisited
  197. Curcumin: a modulator of inflammatory signaling pathways in the immune system
  198. Bariatric Surgery Modulates Urinary Levels of MicroRNAs Involved in the Regulation of Renal Function
  199. Lipids and insulin regulate mitochondrial‐derived peptide (MOTS‐c) in PCOS and healthy subjects
  200. The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study
  201. Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes
  202. Molecular mechanisms of trehalose in modulating glucose homeostasis in diabetes
  203. Effects of curcumin on ion channels and pumps: A review
  204. The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
  205. Comparison of the Neuroprotective Effects of Aspirin, Atorvastatin, Captopril and Metformin in Diabetes Mellitus
  206. Systematic Review and Meta-analysis on the Effect of Soy on Thyroid Function
  207. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome
  208. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function
  209. Metabolic and proteomic signatures of hypoglycaemia in type 2 diabetes
  210. Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
  211. Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women
  212. Platelet function following induced hypoglycaemia in type 2 diabetes
  213. Effects of acute insulin‐induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes
  214. Polycystic Ovary Syndrome: Implication for Drug Metabolism on Assisted Reproductive Techniques—A Literature Review
  215. The Effect of Phytoestrogen on Thyroid in Subclinical Hypothyroidism: Randomized, Double Blind, Crossover Study
  216. Occurrence of deoxynivalenol in an elderly cohort in the UK: a biomonitoring approach
  217. Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters
  218. Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause
  219. Clinical Evaluation of Hypercalcaemia
  220. Investigation Of Pituitary Disease
  221. Corrigendum: The Effect of a Simulated Commercial Flight Environment With Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants With Type 2 Diabetes – A Cross-Over Study
  222. Improved physiology and metabolic flux after Roux-en-Y gastric bypass is associated with temporal changes in the circulating microRNAome: a longitudinal study in humans
  223. Adjustment of the GRACE score by 2-hour post-load glucose improves prediction of long-term major adverse cardiac events in acute coronary syndrome in patients without known diabetes
  224. Correction to: Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes
  225. Salivary and serum androgens with anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome
  226. Effects of Growth Hormone Replacement on Peripheral Muscle and Exercise Capacity in Severe Growth Hormone Deficiency
  227. Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes
  228. The Effect of a Simulated Commercial Flight Environment with Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants with Type 2 Diabetes – A Cross-over Study
  229. Obesity and Polycystic Ovary Syndrome
  230. Anti‐Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome
  231. Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism – a randomised controlled study
  232. The Effects of Acute Interval Exercise and Strawberry Intake on Postprandial Lipemia
  233. The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome
  234. Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency
  235. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
  236. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss
  237. Deoxynivalenol Biomarkers in the Urine of UK Vegetarians
  238. Salivary testosterone measurement in women with and without polycystic ovary syndrome
  239. Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome
  240. Androstenedione and testosterone levels correlate with in vitro fertilization rates in insulin-resistant women
  241. A trial to compare the effect of weight loss diets on obese women with polycystic ovarian syndrome (PCOS)
  242. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
  243. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-Blinded Crossover Study
  244. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
  245. Modelling aspects of oviduct fluid formation in vitro
  246. Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism – A Randomized Controlled Study
  247. Determination of Deoxynivalenol in the Urine of Pregnant Women in the UK
  248. The repeatability of the abbreviated (4-h) Oral Fat Tolerance Test and influence of prior acute aerobic exercise
  249. Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome
  250. Pilot Investigation of a Virtual Gastric Band Hypnotherapy Intervention
  251. Management of type 1 and type 2 diabetes requiring insulin
  252. Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial
  253. Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome
  254. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits
  255. Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
  256. Diabetes and Chocolate: Friend or Foe?
  257. Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study
  258. Sporopollenin, The Least Known Yet Toughest Natural Biopolymer
  259. Pituitary and/or hypothalamic dysfunction following moderate to severe traumatic brain injury: Current perspectives
  260. Insulin induced lipodystrophy
  261. LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation
  262. Microparticle profile in patients with type 2 diabetes
  263. Biological variation of cardiovascular risk factors in patients with diabetes
  264. Database of patients with polycystic ovary syndrome and healthy women
  265. Atorvastatin Reduces Malondialdehyde Concentrations in Patients with Polycystic Ovary Syndrome
  266. Radiotherapy-induced hypopituitarism: a review
  267. Does equol production determine soy endocrine effects?
  268. The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism
  269. MECHANISMS IN ENDOCRINOLOGY: Recent advances in cardiovascular aspects of polycystic ovary syndrome
  270. Endocrine disruptor & nutritional effects of heavy metals in ovarian hyperstimulation
  271. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study
  272. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit
  273. Pituitary hypophysitis and gulf war syndrome: a case series and hypothesis
  274. Postural hypotension
  275. The Effect of Soy Phytoestrogen Supplementation on Thyroid Status and Cardiovascular Risk Markers in Patients with Subclinical Hypothyroidism: A Randomized, Double-Blind, Crossover Study
  276. Pharmacological Treatment of Obesity in Patients with Polycystic Ovary Syndrome
  277. Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant
  278. High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome
  279. Atorvastatin Increases 25-Hydroxy Vitamin D Concentrations in Patients with Polycystic Ovary Syndrome
  280. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients
  281. Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes
  282. Obesity and gestational diabetes
  283. Evidence for statin therapy in polycystic ovary syndrome
  284. Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity
  285. Investigating hirsutism
  286. The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study
  287. Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis
  288. Alterations in thyroid status do not affect plasma peptide YY (PYY) and ghrelin concentrations
  289. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
  290. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging